Alivus Life Sciences Limited
Alivus Life Sciences Limited (ALIVUS) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
alivus.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
|---|---|---|---|---|
| Sales | 650 Cr | 602 Cr | 588 Cr | 673 Cr |
| Operating expenses (approx.) | 451 Cr | 430 Cr | 409 Cr | 442 Cr |
| EBITDA | 198 Cr | 172 Cr | 179 Cr | 231 Cr |
| OPM % | 30.5% | 28.6% | 30.5% | 34.4% |
| Other income | 10 Cr | 9 Cr | 15 Cr | 14 Cr |
| Interest | 1 Cr | 1 Cr | 1 Cr | 1 Cr |
| Depreciation | 16 Cr | 17 Cr | 18 Cr | 20 Cr |
| Profit before tax | 191 Cr | 163 Cr | 174 Cr | 198 Cr |
| Tax % | 25.8% | 25.4% | 25.3% | 24.3% |
| Net profit | 142 Cr | 122 Cr | 130 Cr | 150 Cr |
| EPS (₹) | ₹11.57 | ₹9.91 | ₹10.60 | ₹12.25 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 2,387 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,704 Cr | Sign in for TTM |
| EBITDA | 683 Cr | Sign in for TTM |
| OPM % | 28.6% | Sign in for TTM |
| Other income | 35 Cr | Sign in for TTM |
| Interest | 2 Cr | Sign in for TTM |
| Depreciation | 61 Cr | Sign in for TTM |
| Profit before tax | 654 Cr | Sign in for TTM |
| Tax % | 25.8% | Sign in for TTM |
| Net profit | 486 Cr | Sign in for TTM |
| EPS (₹) | ₹39.63 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 25 Cr |
| Reserves | 2,793 Cr |
| Borrowings | — |
| Other liabilities | 594 Cr |
| Total liabilities | 3,411 Cr |
| Fixed assets (net) | 943 Cr |
| CWIP | 94 Cr |
| Investments | 478 Cr |
| Inventories | 674 Cr |
| Trade receivables | 970 Cr |
| Cash & bank | 71 Cr |
| Other assets | 182 Cr |
| Total assets | 3,411 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | 392 Cr |
| Cash from investing | -616 Cr |
| Cash from financing | -6 Cr |
| Net cash flow | -230 Cr |
| Free cash flow (OCF − Capex) | 225 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | 23.3% |
| ROE % | 17.2% |
| Debtor days | 148 |
| Inventory days | 233 |
| Days payable | 135 |
| Cash conversion cycle | 246 |
| Debt / equity | — |
| Current ratio | 4.97 |
| Net debt / EBITDA | -0.10 |
Compare with peers
Loading peers…